Alchek DS

Alchek DS Eye Drops

Alchek DS, an antihistamine, works by blocking the action of histamine in the body, which reduces allergy symptoms. Alchek DS Hydrochloride treats sneezing, itching, runny nose, and other nasal symptoms of allergies. Alchek DS Nasal Spray contains 0.6% w/v Alchek DS (base) in a nonsterile aqueous solution with pH of approximately 3.7. After initial priming (5 sprays), each metered spray from the nasal applicator delivers 100 microliters of the aqueous solution containing 665 mcg of olopatadine Hydrochloride, which is equivalent to 600 mcg of Alchek DS (base). Alchek DS Nasal Spray also contains benzalkonium chloride (0.01%), dibasic sodium phosphate, edetate disodium, sodium chloride, hydrochloric acid and/or sodium hydroxide (to adjust pH), and purified water.


Alchek DS Nasal Spray is an H1 receptor antagonist used for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older.

Alchek DS is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Seasonal Allergic Conjunctivitis, Seasonal Allergic Rhinitis

Alchek DS

Trade Name Alchek DS
Generic Olopatadine
Olopatadine Other Names Olopatadin, Olopatadina, Olopatadine, Olopatadinum
Weight 0.2%
Type Eye Drops
Formula C21H23NO3
Weight Average: 337.4122
Monoisotopic: 337.167793607
Protein binding

About 55% of total olopatadine is bound to human serum proteins, with serum albumin being the primary protein of binding.

Therapeutic Class Nasal Anti-histamine preparations
Manufacturer Apex Pharmaceuticals Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:23 am


Alchek DS
Olopatadine Structure


Alchek DS dosage

Adults and Adolescents 12 years of age and older: Two sprays per nostril twice daily.

Children 6 to 11 years of age: One spray per nostril twice daily.

Administer Alchek DS Nasal Spray by the intranasal route only.

Side Effects

A bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. Drowsiness may rarely occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.


Before initial use, Alchek DS Nasal Spray by releasing 5 sprays or until a fine mist appears. When Alchek DS Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying Alchek DS Nasal Spray into the eyes. Patients should be informed to avoid spraying Alchek DS Nasal Spray in their eyes.


Interaction with other medications have not been investigated.

Food Interaction

No interactions found.

Volume of Distribution

In an open-label study consisting of healthy Chinese subjects receiving oral administration of olopatadine, the mean apparent volume of distribution was 133.83 L.

Half Life

Following ocular administration, the elimination half-life of olopatadine was 3.4 ± 1.2 hours. In oral pharmacokinetics study, the elimination half-life was reported to be 8 to 12 hours.


In an open-label study consisting of healthy Chinese subjects receiving oral administration of olopatadine, the mean apparent oral clearance (CL/F) was 23.45 L/h.

Pregnancy & Breastfeeding use

Pregnancy Category C; No adequate and well-controlled studies in pregnant women have been conducted. Alchek DS Nasal Spray should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Lactation: It is not known whether topical nasal administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk. Alchek DS Nasal Spray should be used by nursing mothers only if the potential benefit to the patient outweighs the potential risks to the infant.

Special Warning

There have been no reported overdoses with Alchek DS Nasal Spray.

Innovators Monograph

Alchek DS contains Olopatadine see full prescribing information from innovator // generic/olopatadine/olopatadine-hydrochloride-nasal-spray-prescribing-information" Monograph